BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1786484)

  • 1. Prediction and Prevention of Prescription Drug Abuse: Role of Preclinical Assessment of Substance Abuse Liability.
    Marusich JA; Lefever TW; Novak SP; Blough BE; Wiley JL
    Methods Rep RTI Press; 2013 Jul; ():1-14. PubMed ID: 24008590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EVALUATION OF DRUG ABUSE TREATMENT MEDICATIONS: CONCORDANCE BETWEEN CLINICAL AND PRECLINICAL STUDIES.
    Mello NK
    NIDA Res Monogr; 2005 May; 185():82-104. PubMed ID: 16906230
    [No Abstract]   [Full Text] [Related]  

  • 3. A Brief Introduction to Human Behavioral Pharmacology: Methods, Design Considerations and Ethics.
    Stoops WW
    Perspect Behav Sci; 2022 Jun; 45(2):361-381. PubMed ID: 35719875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans.
    Dunn KE; Bergeria CL; Huhn AS; Strain EC
    Front Psychiatry; 2019; 10():704. PubMed ID: 31616329
    [No Abstract]   [Full Text] [Related]  

  • 5. Nicotine addiction: a re-analysis of the arguments.
    West R
    Psychopharmacology (Berl); 1992; 108(4):408-10; discussion 411-6. PubMed ID: 1410153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation and abuse liability testing of medicines in Europe beyond 1992.
    García Alonso F
    Br J Addict; 1991 Dec; 86(12):1533-6. PubMed ID: 1786483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives and future on testing for abuse liability in humans.
    Camí J
    Br J Addict; 1991 Dec; 86(12):1529-31. PubMed ID: 1786482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barcelona meeting on clinical testing of drug abuse liability: consensus statement and recommendations.
    Br J Addict; 1991 Dec; 86(12):1527-8. PubMed ID: 1786481
    [No Abstract]   [Full Text] [Related]  

  • 9. Preclinical assessment of abuse liability of biologics: In defense of current regulatory control policies.
    Gauvin DV; Zimmermann ZJ; Baird TJ
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):43-54. PubMed ID: 26107292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The necessity and utility of abuse liability evaluations in human subjects.
    Vocci FJ
    Br J Addict; 1991 Dec; 86(12):1537-42. PubMed ID: 1786484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Principles of assessment of abuse liability: US legal framework and regulatory environment.
    Rocha BA
    Behav Pharmacol; 2013 Sep; 24(5-6):403-9. PubMed ID: 23820327
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.